Abbvie Inc (ABBV)

$215.36 +2.24 (1.05%)
Market Cap 381.10B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 21.05
Forward PE 15.08
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 2,307,726
Avg Vol 6,716,690
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 56%
Beta 0.32
Analysts Strong Sell
Price Target $250.90

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 7:07 PM
$SLS $ABBV - this $8 Stock Will Be an $80 Stock Phase 3 Registrational Results are Coming.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 6:59 PM
$SLS $ABBV 6 events in the last 4.5 months 1 event every 3 weeks Not that events are linear, this far along an OS curve - 26 months ranging up to 64 months - could see 2 events in single week. - Already been 2.5 weeks since the 78th... The Share Price will continue climbing until the 80th EVENT PR - and then it LAUNCHES.
0 · Reply
jcooptechit
jcooptechit May. 27 at 5:18 PM
$CUE | SMALL-CAP BIOTECH SETUP WITH BIG RE-RATE ENERGY NASDAQ-listed, fresh $30M private placement, Phase 2 exposure with CUE-221, and Big Pharma validation through Boehringer Ingelheim. Key Levels: ✅ Reaccumulation: $18.29–$22.30 ✅ Breakout: $25.56 ✅ Major resistance: $30.74–$33.08 ✅ Target: $41.35+ As long as CUE holds this reaccumulation zone, the structure stays constructive. A move over $25.56 could bring momentum back fast and clearing $33.08 puts $41.35+ in play. Small-cap biotech can move quick when capital, catalysts, and technicals line up. 🔥 Communicated - Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $LLY $JNJ $MRK $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 4:51 PM
$IMGN $SLS Be Holding when the 80th EVENT PR is ANNOUNCED. Expect a 2x 3x+ Move and the share Price will continue CLIMBING. Gps is truly worth Several Tens of billions to big Pharma. -- discussion regarding GPS WT1 Value -- Gps + Pembro/Keytruda Phase 2 Trial Results - achieved Longer Survival for PR/ROC Patients than Elahere/ $IMGN which $ABBV bought for $10.1B Elahere MOS of 16.46 MONTHS / GPS Key 18.4 MONTHS. - Just this 1 Direct Market Comp at $10B GPS is worth Tens of Billions to big Pharma. Even the $MRK Dr. co-authoring the Final P2 DATA, stated Gps warranted further P3 Trials, - this is a massively bullish in Medspeak.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 2:59 PM
$SLS 2 Points: BAT / for control ARM Patients FAILED 3 Large Phase 3 Trials conducted by $ABBV - this $8 Stock Will Be an $80 Stock GPS Phase 3 MOS > 30 Months for CR2/3 Patients is better than the 26/7 Month MOS for Onureg in CR1. - once we get the 80th Event PR - Institutional Funds will be Running all the Numbers - What is GPS WORTH.?. This $8 Stock will be an $80 Stock and Climbing - MARK THIS POST GPS Phase 3 MOS > 30 Months Requires the Market Factor Additional Massive Value for GPS in CR1.
0 · Reply
Loudermilk64
Loudermilk64 May. 27 at 2:59 PM
$ABBV Buy the dip down around here then?
0 · Reply
Mike22332233
Mike22332233 May. 27 at 1:56 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! .. From here, SLS could return 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing !!! ... ALSO, this week I expect the twice delayed TO for $LSTA at $5.00 plus a CVR for another future possible $1.00, to move forward, and from current $3.14 price, to give me a +59% return ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I post my Special Situation Stocks that have potential for FAST & HUGE profits ... which I always plow back into more $SLS !!!
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 5:10 AM
$SLS $ABBV $ABVX When the 80th EVENT is Announced, this is some of the Revenue Institutional Investors and Big Pharma is Looking at.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 3:19 AM
$SLS $ABBV While we are seeing Near Miraculous Survival in ALL POOLED REGAL PHASE 3 Patients, AZA+Ven, the Best Available Treatment / BAT for Control Arm Patients in the REGAL Trial, recently Failed 3 Large Phase 3 Trials. - including Failing the VIALE-M - Phase 3 Maintenance Trial for AML patients in First Remission (CR1). https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=results $ABBV Terminated the Trial at 116 Patients, and didn't make it out of the Safety Phase - they tried 7 different Dosing Schedules, all Oral IV Subq --- Aza+VEN Failed as a Maintenance treatment in CR1 - it is failed is the AML CR2 REGAL Control Arm. Aza+VEN als FAILED the VIALE-T - Post Transplant Maintenance Phase 3. IT IS NOT COMPLICATED...
0 · Reply
semiguy
semiguy May. 26 at 10:31 PM
$PH $A $ABBV $FAI.X I told you last week - Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe 2026 SYMBOL(MX) Magnachip a small cap power solutions semiconductor company based in South Korea. • MKT Cap of $230 million. • Revenue of $180 million. • 8 inch foundry worth approximately 200 million – 36K wafers a month • Cash of $50 million, trading at $5.70 a share. ( as of last Friday) • Won’t be at this price for long. Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe https://www.businesswire.com/news/home/20260526332549/en/Magnachip-to-Showcase-MV-MOSFET-Portfolio-for-AI-Servers-and-Data-Centers-Alongside-Its-Broader-Power-Semiconductor-Portfolio-at-PCIM-Europe-2026
0 · Reply
Latest News on ABBV
AbbVie reports positive CHMP opinion for Maviret

2026-05-22T12:12:15.000Z - 5 days ago

AbbVie reports positive CHMP opinion for Maviret

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 5 days ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 5 days ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

2026-05-21T20:19:37.000Z - 5 days ago

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 5 days ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-15T12:51:42.000Z - 12 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

2026-05-14T20:15:24.000Z - 12 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

AbbVie price target raised to $298 from $294 at Piper Sandler

2026-05-14T11:07:12.000Z - 13 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 14 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

May 9, 2026, 10:08 AM EDT - 18 days ago

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 19 days ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 21 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

2026-05-05T12:32:52.000Z - 22 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 22 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 23 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

May 2, 2026, 8:45 AM EDT - 25 days ago

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AZN GSK

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 26 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 26 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 27 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T18:00:46.000Z - 27 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 27 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 27 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 27 days ago

AbbVie upgraded to Buy at BofA on durable growth

AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 27 days ago

AbbVie upgraded to Buy from Neutral at BofA

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

Apr 29, 2026, 2:50 PM EDT - 4 weeks ago

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:41:09.000Z - 4 weeks ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:58.000Z - 4 weeks ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-04-29T16:39:07.000Z - 4 weeks ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 4 weeks ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 4 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 4 weeks ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 4 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 4 weeks ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 4 weeks ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 4 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 4 weeks ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 5 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 5 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 5 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 6 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 6 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 6 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

Apr 9, 2026, 2:00 PM EDT - 6 weeks ago

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

AMCR CVX

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 7 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 7 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 7 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 7 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 7 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 7 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 7 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 7 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 7 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 2 months ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 2 months ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Mar 6, 2026, 8:26 AM EST - 2 months ago

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

GILD V

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 3 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 3 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 3 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 7:07 PM
$SLS $ABBV - this $8 Stock Will Be an $80 Stock Phase 3 Registrational Results are Coming.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 6:59 PM
$SLS $ABBV 6 events in the last 4.5 months 1 event every 3 weeks Not that events are linear, this far along an OS curve - 26 months ranging up to 64 months - could see 2 events in single week. - Already been 2.5 weeks since the 78th... The Share Price will continue climbing until the 80th EVENT PR - and then it LAUNCHES.
0 · Reply
jcooptechit
jcooptechit May. 27 at 5:18 PM
$CUE | SMALL-CAP BIOTECH SETUP WITH BIG RE-RATE ENERGY NASDAQ-listed, fresh $30M private placement, Phase 2 exposure with CUE-221, and Big Pharma validation through Boehringer Ingelheim. Key Levels: ✅ Reaccumulation: $18.29–$22.30 ✅ Breakout: $25.56 ✅ Major resistance: $30.74–$33.08 ✅ Target: $41.35+ As long as CUE holds this reaccumulation zone, the structure stays constructive. A move over $25.56 could bring momentum back fast and clearing $33.08 puts $41.35+ in play. Small-cap biotech can move quick when capital, catalysts, and technicals line up. 🔥 Communicated - Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $LLY $JNJ $MRK $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 4:51 PM
$IMGN $SLS Be Holding when the 80th EVENT PR is ANNOUNCED. Expect a 2x 3x+ Move and the share Price will continue CLIMBING. Gps is truly worth Several Tens of billions to big Pharma. -- discussion regarding GPS WT1 Value -- Gps + Pembro/Keytruda Phase 2 Trial Results - achieved Longer Survival for PR/ROC Patients than Elahere/ $IMGN which $ABBV bought for $10.1B Elahere MOS of 16.46 MONTHS / GPS Key 18.4 MONTHS. - Just this 1 Direct Market Comp at $10B GPS is worth Tens of Billions to big Pharma. Even the $MRK Dr. co-authoring the Final P2 DATA, stated Gps warranted further P3 Trials, - this is a massively bullish in Medspeak.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 2:59 PM
$SLS 2 Points: BAT / for control ARM Patients FAILED 3 Large Phase 3 Trials conducted by $ABBV - this $8 Stock Will Be an $80 Stock GPS Phase 3 MOS > 30 Months for CR2/3 Patients is better than the 26/7 Month MOS for Onureg in CR1. - once we get the 80th Event PR - Institutional Funds will be Running all the Numbers - What is GPS WORTH.?. This $8 Stock will be an $80 Stock and Climbing - MARK THIS POST GPS Phase 3 MOS > 30 Months Requires the Market Factor Additional Massive Value for GPS in CR1.
0 · Reply
Loudermilk64
Loudermilk64 May. 27 at 2:59 PM
$ABBV Buy the dip down around here then?
0 · Reply
Mike22332233
Mike22332233 May. 27 at 1:56 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! .. From here, SLS could return 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing !!! ... ALSO, this week I expect the twice delayed TO for $LSTA at $5.00 plus a CVR for another future possible $1.00, to move forward, and from current $3.14 price, to give me a +59% return ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I post my Special Situation Stocks that have potential for FAST & HUGE profits ... which I always plow back into more $SLS !!!
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 5:10 AM
$SLS $ABBV $ABVX When the 80th EVENT is Announced, this is some of the Revenue Institutional Investors and Big Pharma is Looking at.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 27 at 3:19 AM
$SLS $ABBV While we are seeing Near Miraculous Survival in ALL POOLED REGAL PHASE 3 Patients, AZA+Ven, the Best Available Treatment / BAT for Control Arm Patients in the REGAL Trial, recently Failed 3 Large Phase 3 Trials. - including Failing the VIALE-M - Phase 3 Maintenance Trial for AML patients in First Remission (CR1). https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=results $ABBV Terminated the Trial at 116 Patients, and didn't make it out of the Safety Phase - they tried 7 different Dosing Schedules, all Oral IV Subq --- Aza+VEN Failed as a Maintenance treatment in CR1 - it is failed is the AML CR2 REGAL Control Arm. Aza+VEN als FAILED the VIALE-T - Post Transplant Maintenance Phase 3. IT IS NOT COMPLICATED...
0 · Reply
semiguy
semiguy May. 26 at 10:31 PM
$PH $A $ABBV $FAI.X I told you last week - Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe 2026 SYMBOL(MX) Magnachip a small cap power solutions semiconductor company based in South Korea. • MKT Cap of $230 million. • Revenue of $180 million. • 8 inch foundry worth approximately 200 million – 36K wafers a month • Cash of $50 million, trading at $5.70 a share. ( as of last Friday) • Won’t be at this price for long. Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe https://www.businesswire.com/news/home/20260526332549/en/Magnachip-to-Showcase-MV-MOSFET-Portfolio-for-AI-Servers-and-Data-Centers-Alongside-Its-Broader-Power-Semiconductor-Portfolio-at-PCIM-Europe-2026
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 26 at 7:54 PM
$SLS Smarter Money than Us is buying Every Cheap Share Idiots will Sell. - it is not complicated, while we await and are seeing Near Miraculous All Pooled Survival, BAT for CONTROL ARM Patients - AZA +VEN - Recently Failed 3 Large Phase 3 Trials conducted by $ABBV go look "WITH RESULTS"
0 · Reply
MarketBeat
MarketBeat May. 26 at 4:01 PM
https://marketbeat.com/a/8675686/ $ABBV 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade
0 · Reply
Loudermilk64
Loudermilk64 May. 26 at 3:53 PM
$ABBV depreasing…
0 · Reply
crtlabz
crtlabz May. 26 at 2:24 PM
$ABBV geez!
0 · Reply
PlutoAnalyses
PlutoAnalyses May. 26 at 9:42 AM
Looking at the current state of the Anti-Obesity Market, it seems that a $VKTX acquisition would likely take one of a few forms. Either a company like $ABBV or $PFE, if they fail a trial or realize their asset isn’t sufficient, might decide to acquire their way into the market. Alternatively, a company with no existing Anti-Obesity exposure, such as $SAN, could choose to enter through an acquisition. It's both promising and somewhat concerning that nearly all the major players in the market have some form of Anti-Obesity asset. On one hand, this shows strong interest, but on the other, it suggests these assets might need to fail first before we see any significant moves.
2 · Reply
jenfierf
jenfierf May. 26 at 9:01 AM
$ABBV appears to be doing well. Bulls are still in control over $215 thanks to a defensive setup and strong volume. observing a move in the direction of $220.
0 · Reply
Mike22332233
Mike22332233 May. 25 at 11:38 PM
$SLS Are you ready for Tuesday Morning? ... UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! .. From here, SLS could return 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing !!! ... ALSO, this week I expect the twice delayed TO for $LSTA at $5.00 plus a CVR for another future possible $1.00, to move forward, and from current $3.14 price, to give me a +59% return ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I post my Special Situation Stocks that have potential for FAST & HUGE profits ... which I always plow back into more $SLS !!!
1 · Reply
StockTwitsGhost
StockTwitsGhost May. 25 at 10:17 PM
$IRWD $ABBV Approved: NDA 202811/S-023 for LINZESS/LINACLOTIDE functional constipation in children ages 2 to 5, AbbVie, SUPPL-23, action date 05/21/2026, Efficacy-New Patient Population. It’s right there on the primary Drugs@ FDA: FDA-Approved Drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 25 at 7:55 PM
$SLS $ABBV Best Available Treatment / BAT for Control Arm Patients in the REGAL Trial, recently Failed 3 Large Phase 3 Trials. - including Failing the VIALE-M - Phase 3 Maintenance Trial for AML patients in First Remission (CR1). $ABBV Terminated the Trial at 116 Patients, and didn't make it out of the Safety Phase - they tried 7 different Dosing Schedules, all Oral IV Subq --- Aza+VEN Failed as a Maintenance treatment in CR1 - it is failed is the AML CR2 REGAL Control Arm. https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=results Aza+VEN als FAILED the VIALE-T - Post Transplant Maintenance Phase 3. IT IS NOT COMPLICATED... $CING
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 25 at 5:12 PM
$SLS $ABBV It is Not Complicated.
0 · Reply
uhnyu678
uhnyu678 May. 25 at 10:14 AM
$ABBV appears to be doing well. When dips continue to be purchased, it typically indicates that buyers are still in charge.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 25 at 6:03 AM
$SLS $ABBV Since the IDMC Unblinded KEY Median Overall Survival and Immune Response data from the Ongoing Phase 3 Interim Analysis - SLS Market Value is up over 1,000%. Actual P3 MOS AND IR DATA. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply